Advertisement

Critical Review of Existing Trials

Part of the Topics in Neuroscience book series (TOPNEURO)

Abstract

Epidemiological studies indicate that about 90% of multiple sclerosis (MS) patients experience a progression of the disease at some time during their life [1, 2]. In about 15% of patients, the disease starts with an insidious onset followed by a progressive phase, with or without phases of stability; the so-called primary progressive (PP) MS. In all other patients, the early phase of MS is marked by acute attacks characterized by unifocal (2/3 of patients) or multifocal white matter disease [3]. Attacks are usually followed by complete or almost complete recovery; however, pathological studies demonstrate the presence of an axonal transection inside the lesion [4, 5, 6]. Axonal loss is predominant in lesions appearing in the early phases of the disease [7] and decreases over time. A large amount of damage occurs in areas with a considerable infiltration of T lymphocytes (especially CD8+ T cells) and macrophages [7], indicating a correlation between inflammation and axonal damage - a relationship which has also been shown by magnetic resonance imaging (MRI) studies. The acute axonal damage also occurs because of the products of inflammation, such as nitric oxide and tumor necrosis factor [8]. Recent studies indicate that a high level of electrical activity may increase the axonal degeneration of partially or completely demyelinated lesions at the nodes of Ranvier, as a consequence of the activation of glutamate receptors increasing the entry of calcium into the axon [9]. Recent studies suggest that axonal damage may also be independent of demyelination [10] and may be caused by antibodies against axonal antigens [11].

Keywords

Multiple Sclerosis Glatiramer Acetate Progressive Multiple Sclerosis Clinically Isolate Syndrome Secondary Progressive Multiple Sclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weinshenker BG, Bass B, Rice GHPA et al (1989) The natural history of multiple sclerosis: a geographical based study 1. Clinical course and disability. Brain 112:133–146PubMedCrossRefGoogle Scholar
  2. 2.
    Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117–134PubMedCrossRefGoogle Scholar
  3. 3.
    Wingerchuk DM, Weinshenker BG (2000) Multiple sclerosis: epidemiology, genetic, classification, natural history and clinical outcome measures. Neuroimaging Clin N Am 10:611–623PubMedGoogle Scholar
  4. 4.
    Ferguson B, Matyszak MK, Esiri MM, Perry VH ( 1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399PubMedCrossRefGoogle Scholar
  5. 5.
    Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. New Engl J Med 338:278–285PubMedCrossRefGoogle Scholar
  6. 6.
    Kornek B, Storech MK, Weissert R et al (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis. Am J Pathol 157:267–276PubMedGoogle Scholar
  7. 7.
    Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212PubMedCrossRefGoogle Scholar
  8. 8.
    Smith KJ, Kapoor R, Felts PA (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49:470–476PubMedCrossRefGoogle Scholar
  9. 9.
    Kapoor R, Davied M, Blaker PA et al (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174–180PubMedCrossRefGoogle Scholar
  10. 10.
    Bitsch A, Schuchardt J, Bunkowski S et al (2000) Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123:1174–1183PubMedCrossRefGoogle Scholar
  11. 11.
    Raine C, Cannella B, Hauser S, Genain C (1999) Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 46:144–160PubMedCrossRefGoogle Scholar
  12. 12.
    Filippi M, Inglese M, Rovaris M et al (2000) Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology 55:940–946PubMedGoogle Scholar
  13. 13.
    Iannucci G, Tortorella C, Rovaris M et al (2001) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 21:1034–1038Google Scholar
  14. 14.
    Sater RA, Rostami AM, Galetta S et al (1999) Serial evoked potential studies and MRI imaging in chronic progressive multiple sclerosis. J Neurol Sci 171(2):79–83PubMedCrossRefGoogle Scholar
  15. 15.
    Leocani L, Comi G (2000) Neurophysiological investigations in multiple sclerosis. Curr Opin Neurol 13:255–261PubMedCrossRefGoogle Scholar
  16. 16.
    Rocca MA, Mastronardo G, Rodegher M et al (1999) Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. Am J Neuroradiol 20:821–827PubMedGoogle Scholar
  17. 17.
    Linington C, Engelhardt B, Kapocs G, Lassmann H (1992) Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 40:219–224PubMedCrossRefGoogle Scholar
  18. 18.
    Lucchinetti C, Bruck W, Parisi J et al (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 122:2279–2295PubMedCrossRefGoogle Scholar
  19. 19.
    European Study Group on Interferon β-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon β-lb in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497CrossRefGoogle Scholar
  20. 20.
    Miller DH, Molyneux PD, Barker GJ et al (1999) Effect of interferon β-lb on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 46:850–859PubMedCrossRefGoogle Scholar
  21. 21.
    North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788–1795Google Scholar
  22. 22.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–1504Google Scholar
  23. 23.
    Li DKB, Zhao GJ, Paty DW (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505–1513PubMedGoogle Scholar
  24. 24.
    Cohen JA, Cutter GR, Fischer JS et al (2002) Benefit of interferon β-la on MSFC progression in secondary progressive MS. Neurology 59:679–687PubMedGoogle Scholar
  25. 25.
    Andersen O, Elovaara I, Färkkilä M et al (2004) Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiat 75:706–710PubMedCrossRefGoogle Scholar
  26. 26.
    The Once Weekly Interferon for MS Study Group (OWIMS) (1999) Evidence of interferon β-la dose response in relapsing-remitting MS: The OWIMS Study. Neurology 53:679–686Google Scholar
  27. 27.
    Kappos L, Weinshenker B, Pozzilli C et al (2004) Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63:1779–1787PubMedGoogle Scholar
  28. 28.
    Leary SM, Thomson AJ (2003) Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 206:215–216PubMedCrossRefGoogle Scholar
  29. 29.
    Montalban X, Thomson AJ (2002) Workshop on primary progressive multiple sclerosis: meeting summary. Mult Scler 8:177–178PubMedCrossRefGoogle Scholar
  30. 30.
    Bornstein MB, Miller A, Teitelbaum D et al (1982) Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 11:317–319PubMedCrossRefGoogle Scholar
  31. 31.
    Bornstein MB, Miller A, Slagle S et al (1987) A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. New Engl J Med 317:408–414PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson KP, Brooks BR, Cohen JA et al and Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of the phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1296–1276Google Scholar
  33. 33.
    Comi G, Filippi M, Wolinsky JS and the European-Canadian Glatiramer Acetate Study Group (2001) The European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis. Ann Neurol 49:290–297PubMedCrossRefGoogle Scholar
  34. 34.
    Bornstein MB, Miller A, Slagle S et al (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533–539PubMedGoogle Scholar
  35. 35.
    Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557–563PubMedCrossRefGoogle Scholar
  36. 36.
    Hommes OR, Sorensen PS, Fazekas F et al (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149–1156PubMedCrossRefGoogle Scholar
  37. 37.
    Fazekas F, Sorensen PS, Filippi M et al (2005) MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 11:433–440PubMedCrossRefGoogle Scholar
  38. 38.
    Filippi M, Rocca MA, Pagani E et al (2004) European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 61:1409–1412PubMedCrossRefGoogle Scholar
  39. 39.
    Hommes OR, Prick JJG, Lamers KJB (1975) Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78:59–73PubMedCrossRefGoogle Scholar
  40. 40.
    Gonsette R, Demonty L, Delmotte P (1977) Intensive immunosuppression with cyclophosphamide in remittent forms of multiple sclerosis: follow up of 110 patients for 2–6 years. J Neuroimmunol 214:173–181Google Scholar
  41. 41.
    Hauser SL, Dawson DM, Lehrich JR et al (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308:173–180PubMedCrossRefGoogle Scholar
  42. 42.
    Canadian Cooperative Study Group (1991) The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441–446Google Scholar
  43. 43.
    Likowsky VH, Fireman B, Elmore R et al (1991) Intensive immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiat 54:1055–1060CrossRefGoogle Scholar
  44. 44.
    Weiner HL, Mackin GA, Orav EJ et al (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910–918PubMedGoogle Scholar
  45. 45.
    Gobbini MI, Smith ME, Richert ND et al (1999) Effect of open-label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142–149PubMedCrossRefGoogle Scholar
  46. 46.
    Perini P, Gallo P (2003) Cyclophosphamide is effective in stabilizing rapidly deteriorating SPMS. J Neurol 250:834–838PubMedCrossRefGoogle Scholar
  47. 47.
    Smith DR, Weinstock-Guttman B, Cohen JA et al (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 11:573–582PubMedCrossRefGoogle Scholar
  48. 48.
    Fidler JM, Dejoy SQ, Gibbons JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone I. Suppression of B lymphocyte function. J Immunol 137:727–732PubMedGoogle Scholar
  49. 49.
    Fidler JM, Dejoy SQ, Smith FR 3rd, Gibbons JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone II. Nonspecific adherent suppressor cells derived from mitoxantrone. J Immunol 136:2747–2754PubMedGoogle Scholar
  50. 50.
    Millefiorini E, Gasperini C, Pozzilli C et al (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24 month clinical and MRI outcome. J Neurol 244:153–59PubMedCrossRefGoogle Scholar
  51. 51.
    Edan G, Miller D et al (1995) Evaluation of the efficacy of mitoxantrone by use of MRI: a multicenter randomized study in multiple sclerosis. Neurology 242(Suppl 2): S38 [abstract]Google Scholar
  52. 52.
    Hartung HP, Gonsette R, Kwiecinski H et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025PubMedCrossRefGoogle Scholar
  53. 53.
    van de Wyngaert FA, Beguin C, D’Hooghe MB et al (2001) A double blind clinical trial of mitoxantrone versus methylprednisolone in relapsing secondary progressive multiple sclerosis. Acta Neurol Belg 244:153–159Google Scholar
  54. 54.
    Krapf H, Morrissey SP, Zenker O et al (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65:690–695PubMedCrossRefGoogle Scholar
  55. 55.
    Martinelli Boneschi F, Rovaris M, Capra R, Comi G (2005) Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 4:CD002127Google Scholar
  56. 56.
    Fox EJ (2006) Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Therapeut 28:461–474CrossRefGoogle Scholar
  57. 57.
    Jammohammed R, Milligan DW (1989) Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. Br J Haematol 71:292–293Google Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • G. Comi
    • 1
  1. 1.Department of NeurologyScientific Institute and University Ospedale San RaffaeleMilanItaly

Personalised recommendations